Background: We aim to evaluate the treatment value and safety of hydroxychloroquine (HCQ)/ chloroquine (CQ) in COVID-19.
Methods: We retrospectively reviewed the medical charts of patients with COVID-19 admitted to an inpatient ward in Wuhan from 2020. 02. 08 to 2020. 03. 05. Patients with HCQ/ CQ and age, gender, disease severity matched ones without HCQ/ CQ were selected at a 1:2 ratio. The clinical, laboratory and imaging findings were compared between these two groups. The multivariate linear regression analysis was performed to identify the factors that might influence patients’ virus shedding periods (VSPs).
Results: A total of 14 patients with HCQ/ CQ and 21 matched were analyzed. The HCQ/CQ treatment lasted for an average of 10.36±3.12 days. The VSPs were a little longer in the HCQ/ CQ treatment group (26.57±10.35 days vs. 19.10±7.80 days, P=0.020). There were 3 patients deceased during inpatient period, two patients were with HCQ/ CQ treatment (P=0.551). In the multivariate linear regression analysis, disease durations at admission (t=3.643, P=0.001) and HCQ/CQ treatment (t=2.637, P=0.013) were independent parameters for patients’ VSPs prediction. One patient with CQ had recurrent first-degree atrioventricular block (AVB) and obvious QTc elongation, another one complained about dizziness and blurred vision which disappeared after CQ discontinuation. One patient with HCQ had transient AVB.
Conclusions: The HCQ/ CQ administration is not related to neither less mortality cases nor shorter VSPs. HCQ rather than CQ is relative safe and tolerable.